SCHEMBL7606291

SCHEMBL7606291

Cn1nc(-c2ccccc2)cc1NC=C1C(=O)Nc2ncc(-c3ccccc3)cc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK3 P52333 1/20 0.41
MAPT P10636 7/20 0.39
POLB P06746 1/20 0.39
RAB9A P51151 1/20 0.38
MAP3K11 Q16584 2/20 0.38
XBP1 P17861 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
NTRK1 P04629 4/20 0.37
CHEK1 O14757 1/20 0.37
AURKA O14965 1/20 0.37
DAPK3 O43293 1/20 0.37
PRKD3 O94806 1/20 0.37
MAP4K4 O95819 1/20 0.37
ABL1 P00519 1/20 0.37
CSF1R P07333 1/20 0.37
RET P07949 1/20 0.37
MET P08581 1/20 0.37
PDGFRB P09619 1/20 0.37
PIM1 P11309 1/20 0.37
FGFR1 P11362 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7606283 1.00 JAK3 (0.41) JAK3MAPTPOLBRAB9AMAP3K11
SCHEMBL7616064 0.91 CDK8 (0.37) JAK3MAPTPOLBRAB9AMAP3K11
SCHEMBL7616071 0.91 CDK8 (0.37) JAK3MAPTPOLBRAB9AMAP3K11
SCHEMBL7609671 0.90 NTRK1 (0.46) JAK3MAPTPOLBRAB9AXBP1
SCHEMBL7609675 0.90 NTRK1 (0.46) JAK3MAPTPOLBRAB9AXBP1
SCHEMBL7612207 0.89 MAPT (0.35) JAK3MAPTPOLBRAB9AMAP3K11
SCHEMBL7612214 0.89 MAPT (0.35) JAK3MAPTPOLBRAB9AMAP3K11
SCHEMBL7723563 0.86 RAF1 (0.43) MAPTPOLBRAB9AXBP1NPSR1
SCHEMBL7613347 0.83 SMN1; SMN2 (0.40) MAPTPOLBRAB9ANTRK1
SCHEMBL7613340 0.83 SMN1; SMN2 (0.40) MAPTPOLBRAB9ANTRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020099071-A1 Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia GLENNON KIMBERLEY CAROLINE (US) 2002-07-25 US claimed
EP-1165514-A1 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2002-01-02 EP claimed
WO-2000056710-A1 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2000-09-28 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099071-A1 Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia PRKDC, PRKX, BMX JAK3 173/4885MAPT 2317/4885POLB 3589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.